Characteristics | Pre-recommendation 1078 Pts. (75.6%) | Post-recommendation 347 Pts. (24.3%) | P-value |
---|---|---|---|
Age, median [IQR] | 73 [67–79] | 69 [64–76] | |
Age at diagnosis, mean [range] | 68.4 [40–96] | 69.1 [47–91] | 0.274 |
Age categories, n (%) | <.0001 | ||
- < 50 years | 4 (0.4%) | 4 (1.1%) | |
- 50–74 years | 615 (57%) | 246 (70.8%) | |
- ≥75 years | 459 (42.6%) | 97 (27.9%) | |
PSA (ng/ml), median [IQR] | 7.1 [5.2–11.5] | 8.8 [6.4–13.4] | 0.037 |
PSA categories, n (%) | 0.011 | ||
- ≤4 | 90 (8.4%) | 23 (6.6%) | |
- 4.01–10 | 652 (60.4%) | 183 (52.7%) | |
- 10.01–20 | 204 (18.9%) | 89 (25.7%) | |
- > 20 | 132 (12.2%) | 52 (15%) | |
Prostate volume (ml3), median [IQR] | 34.8 [26.4–47.1] | 40.3 [29.6–56.9] | <.0001 |
PSA density (ng/ml/ml3), median [IQR] | 0.21 [0.14–0.336 | 0.22 [0.12–0.38] | 0.756 |
Gleason score | <.0001 | ||
- Gleason 6 | 473 (43.9%) | 93 (26.8%) | |
- Gleason 7 | 327 (30.3%) | 146 (42.1%) | |
- Gleason 8–10 | 278 (25.8%) | 108 (31.1%) | |
Clinical stage | 0.035 | ||
- T1-2a | 669 (62.1%) | 190 (54.7%) | |
- 2b | 252 (23.4%) | 103 (29.7%) | |
- 2c-3a | 157 (14.5%) | 54 (15.6%) | |
D’Amico risk classification | <.0001 | ||
- Low | 399 (37%) | 78 (22.4%) | |
- Intermediate | 356 (33%) | 147 (42.4%) | |
- High | 323 (30%) | 122 (34.8%) |